Develops translational therapies for neurodegenerative disease across oligonucleotide, biologic, antibody-drug-conjugate, and gene-therapy platforms. Prior academic work established antisense-oligonucleotide strategies for lowering tau, generating preclinical evidence that supported clinical development for Alzheimer's disease.